Skip to main content
. 2022 Dec 31;15(3):515–524. doi: 10.1038/s41385-021-00482-8

Fig. 3.

Fig. 3

Post COVID-19 MDM produce increased amounts of inflammatory 5-lipoxygenase metabolites.aFASN and SEMA7A expression in seronegative (n = 8) and post CoV MDM (n = 16). b Gene expression of FASN and ALOX5 in seronegative (n = 6/20) or post CoV (n = 6/19) CD14+ PBMCs. c PCA of lipid mediator profiles of MDM from seronegative (n = 22) or seropositive (n = 47) individuals. Red and blue circles: 95% CI. d Heatmap of lipid mediators produced by seronegative (n = 22) or post CoV (n = 47) MDM (LC-MS/MS). Clustering: with k-means using Pearson correlation. Data is shown as mean. e Sum of z-scored arachidonic acid derived 5-LOX metabolite concentrations for each donor. Levels of major 5-LOX (e, h) and COX (f, i) metabolites produced by MDM at 3-5 (e, f) or 12 (h, i) months p.i. (LC-MS/MS) shown as mean + SEM of n = 22/ n = 4 seronegative or n = 47/n = 10 seropositive individuals. g Expression of ALOX5 and LTA4H (RNAseq) in MDM from seronegative (n = 8) or post CoV (n = 16) individuals. j IgG titers in serum or number of symptoms in MDM from post CoV donors stratified into 5-LOX low (z-score < 1) and high producers (z-score > 1). Bar graphs are depicted as mean + SEM. Statistical significance was determined by Mann–Whitney test. *p < 0.05; **p < 0.01; ***p < 0.001.